Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection

被引:134
|
作者
Theil, FP [1 ]
Guentert, TW [1 ]
Haddad, S [1 ]
Poulin, P [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Drug Safety, Pharma Res, CH-4070 Basel, Switzerland
关键词
drug discovery; drug development; partition coefficients; PBPK modeling; pharmacokinetics; toxicokinetics; QSAR;
D O I
10.1016/S0378-4274(02)00374-0
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present paper proposes a modeling and simulation strategy for the prediction of pharmacokinetics (PK) of drug candidates by using currently available in silico and in vitro based prediction tools for absorption, distribution, metabolism and excretion (ADME). These methods can be used to estimate specific ADME parameters (such as rate and extent of absorption into portal vein, volume of distribution, metabolic clearance in the liver). They can also be part of a physiologically based pharmacokinetic (PBPK) model to simulate concentration-time profiles in tissues and plasma resulting from the overall PK after intravenous or oral administration. Since the ADME prediction tools are built only on commonly generated in silico and in vitro data, they can be applied already in early drug discovery, prior to any in vivo study. With the suggested methodology, the following advantages of the mechanistic PBPK modeling framework can now be utilized to explore potential clinical candidates already in drug discovery: (i) prediction of plasma (blood) and tissue PK of drug candidates prior to in vivo experiments, (ii) supporting a better mechanistic understanding of PK properties, as well as helping the development of more rationale PK-PD relationships from tissue kinetic data predicted, and hence facilitating a more rational decision during clinical candidate selection, and (iii) the extrapolation across species, routes of administration and dose levels. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 49
页数:21
相关论文
共 50 条
  • [31] ROLE OF COMPUTER AIDED DRUG DESIGN IN DRUG DEVELOPMENT AND DRUG DISCOVERY
    Bisht, Neema
    Singh, B. K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (04): : 1405 - 1415
  • [32] The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation
    Siccardi, Marco
    Rannard, Steve
    Owen, Andrew
    ADVANCED DRUG DELIVERY REVIEWS, 2018, 131 : 116 - 121
  • [33] Insight into Tissue Unbound Concentration: Utility in Drug Discovery and Development
    Mariappan, T. Thanga
    Mandlekar, Sandhya
    Marathe, Punit
    CURRENT DRUG METABOLISM, 2013, 14 (03) : 324 - 340
  • [34] Pharmacokinetic Properties and In Silico ADME Modeling in Drug Discovery
    Honorio, Kathia M.
    Moda, Tiago L.
    Andricopulo, Adriano D.
    MEDICINAL CHEMISTRY, 2013, 9 (02) : 163 - 176
  • [35] Development and specification of physiologically based pharmacokinetic models for use in risk assessment
    Clewell, Rebecca A.
    Clewell, Harvey J., III
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2008, 50 (01) : 129 - 143
  • [36] A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
    Sjogren, Erik
    Tarning, Joel
    Barnes, Karen, I
    Jonsson, E. Niclas
    PHARMACEUTICS, 2021, 13 (02) : 1 - 23
  • [37] Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach
    Schaller, Stephan
    Martins, Frederico S.
    Balazki, Pavel
    Bohm, Sonja
    Baumgart, Joachim
    Hilger, Ralf A.
    Beelen, Dietrich W.
    Hemmelmann, Claudia
    Ring, Arne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1722 - 1734
  • [38] A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib
    Wang, Ziteng
    Xiang, Xiaoqiang
    Liu, Shuaibing
    Tang, Zhijia
    Sun, Hong
    Parvez, Masud
    Ghim, Jong-Lyul
    Shin, Jae-Gook
    Cai, Weimin
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 39
  • [39] Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
    Amore, Benny M.
    Gibbs, John P.
    Emery, Maurice G.
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2010, 13 (02) : 207 - 218
  • [40] Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson, Trevor N.
    Ke, Alice B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 : S83 - S93